Regulation of cannabis by the federal government, specifically the Food & Drug Administration, was unthinkable less than a decade ago, but it will someday soon be a reality. The FDA is already aware of the non-approved uses of cannabis to treat conditions such as AIDS wasting, epilepsy, neuropathic pain, and several others. The agency has also approved one cannabis-derived drug product: Epidiolex (cannabidiol), used to treat seizures, and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone), all of which treat nausea due to chemotherapy. These approvals don’t signal a trend toward legalization of cannabis, but they do show that the FDA’s studies of cannabis are starting to bear some fruit.
The most recent official guidance from the FDA regarding cannabis regulation was published in January 2021. In this communication, the FDA reassured readers that they are aware of the public interest in using cannabis to develop treatments and consumer products. But the FDA is known for being cautious. The stakes for getting it wrong are high when measured in lives lost. To make matters more complicated, the public is divided on the benefits and dangers of cannabis. However, with other countries experimenting with or outright approving cannabis, the FDA is clearly feeling the pressure to move on the issue of cannabis regulation in the United States.
This CLE will discuss the FDA’s current stance and what needs to happen to move the needle on the FDA’s regulation of cannabis. The discussion will be led by a panel of three cannabis regulation experts. Amber Littlejohn will serve as moderator. Littlejohn is the executive director of the Minority Cannabis Business Association in Washington, D.C., and director of the U.S. Hemp Authority. Patrick Goggin and Garrett Graff will round out the panel. Goggin is a Senior Attorney with the Hoban Law Group specializing in assisting both large and small cannabis businesses. Graff is a partner is Moye White LLP and nationally recognized as a Cannabis Law Trailblazer by National Law Journal.
This program is a must for anyone in the professional cannabis business who is eagerly awaiting FDA regulation and all the changes that come with it.
The most recent official guidance from the FDA regarding cannabis regulation was published in January 2021. In this communication, the FDA reassured readers that they are aware of the public interest in using cannabis to develop treatments and consumer products. But the FDA is known for being cautious. The stakes for getting it wrong are high when measured in lives lost. To make matters more complicated, the public is divided on the benefits and dangers of cannabis. However, with other countries experimenting with or outright approving cannabis, the FDA is clearly feeling the pressure to move on the issue of cannabis regulation in the United States.
This CLE will discuss the FDA’s current stance and what needs to happen to move the needle on the FDA’s regulation of cannabis. The discussion will be led by a panel of three cannabis regulation experts. Amber Littlejohn will serve as moderator. Littlejohn is the executive director of the Minority Cannabis Business Association in Washington, D.C., and director of the U.S. Hemp Authority. Patrick Goggin and Garrett Graff will round out the panel. Goggin is a Senior Attorney with the Hoban Law Group specializing in assisting both large and small cannabis businesses. Graff is a partner is Moye White LLP and nationally recognized as a Cannabis Law Trailblazer by National Law Journal.
This program is a must for anyone in the professional cannabis business who is eagerly awaiting FDA regulation and all the changes that come with it.
